Status:
UNKNOWN
Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive
Lead Sponsor:
Peking University First Hospital
Conditions:
COVID-19
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
To investigate the mechanism, clinical outcome and therapeutic efficacy with favipiravir of Corona Virus Disease 2019 patients whose nucleic acids changed from negative to positive.
Detailed Description
In clinical institutions that enroll corona virus disease 2019 patients whose nucleic acids changed from negative to positive, two arms, multi-center, randomized and controlled methods are adopted. Pa...
Eligibility Criteria
Inclusion
- COVID-19 has been diagnosed, and the nucleic acid test of respiratory specimens such as sputum or nasopharyngeal swabs has been negative for two consecutive times after treatment (sampling time interval of at least 24 hours);
- The nucleic acid test of specimens such as sputum, throat swabs, blood, feces and other specimens was positive for COVID-19 during screening visits;
- Voluntarily participate in research and sign informed consent.
Exclusion
- Those allergic to fapilavir;
- Pregnant or lactating women;
- Unstable liver, kidney, and heart diseases;
- History of mental disorders, substance abuse or dependence;
- Researchers consider it inappropriate to participate in research;
- Participating in other clinical research.
Key Trial Info
Start Date :
April 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 15 2020
Estimated Enrollment :
210 Patients enrolled
Trial Details
Trial ID
NCT04333589
Start Date
April 1 2020
End Date
September 15 2020
Last Update
April 24 2020
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second People's Hospital of Fuyang
Fuyang, Anhui, China, 230022
2
Ezhou Hospital of Traditional Chinese Medicine
Ezhou, Hubei, China, 436000
3
Ezhou Central Hospital
Wuhan, Hubei, China, 430000
4
Huoshenshan Hospital of Wuhan
Wuhan, Hubei, China, 430000